UCB (OTCMKTS:UCBJF) Shares Gap Down – Should You Sell?

UCB SA (OTCMKTS:UCBJF) shares gapped down prior to trading on Wednesday. The stock had previously closed at $328.91, but opened at $314.48. UCB shares last traded at $314.48, with a volume of 27 shares changing hands.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Piper Sandler restated a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Jefferies Financial Group raised UCB to a “hold” rating in a research note on Monday, August 3rd. Finally, Stephens reissued an “overweight” rating on shares of UCB in a research report on Wednesday, October 21st. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy”.

UCB Stock Down 4.4%

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The business’s 50 day moving average price is $262.64 and its 200-day moving average price is $286.33.

About UCB

UCB is a Belgian biopharmaceutical company founded in 1928 and headquartered in Brussels. It discovers, develops and commercializes medicines, with a focus on neurological and immunological conditions. Its products include treatments for epilepsy, such as Keppra, Briviact and Nayzilam, as well as medicines for inflammatory diseases, including Cimzia and Bimzelx. UCB also develops therapies for other serious conditions, including myasthenia gravis. The company serves patients and healthcare providers in markets around the world.